Key Facts

Benzodiazepine dependence is one of the most common forms of substance dependence. It may be iatrogenic (from prescribing) or related to recreational/illicit use. Withdrawal is medically serious and potentially fatal, requiring careful managed reduction rather than abrupt cessation.

Epidemiology

• Approximately ~11 million benzodiazepine prescriptions per year in England
• Estimated ~1 million long-term users in the UK
• Dependence can develop after as little as 4-6 weeks of regular use
• Z-drugs (zopiclone, zolpidem): similar problem; often overlooked
• Illicit benzodiazepine use: increasing problem; novel benzodiazepines (e.g. flualprazolam, etizolam) entering the illicit drug supply
• Benzodiazepines implicated in approximately 40% of opioid-related deaths as co-ingestants

Aetiology

• Pharmacological: benzodiazepines enhance GABA-A receptor function → anxiolysis, sedation, muscle relaxation, anticonvulsant effect
• Tolerance: develops to sedative and anxiolytic effects within 2-4 weeks; less tolerance develops to amnestic effects
• Physical dependence: chronic GABA-A receptor modulation → compensatory downregulation; abrupt cessation → CNS hyperexcitability
• Iatrogenic dependence: most common pathway; prescribed for insomnia/anxiety without time-limited use
• Recreational/illicit use: self-medication, enhancing effects of other drugs, managing stimulant/opioid withdrawal

Pathophysiology

• Chronic benzodiazepine exposure → GABA-A receptor downregulation and conformational changes
• Compensatory upregulation of excitatory (glutamatergic) pathways
• Abrupt cessation → reduced GABAergic inhibition + unopposed glutamatergic excitation → withdrawal syndrome
• Similar mechanism to alcohol withdrawal — cross-tolerance exists between benzodiazepines and alcohol
• Short-acting benzodiazepines (e.g. lorazepam, alprazolam) associated with more rapid onset and more severe withdrawal

Dependence Features

• Tolerance: need for increasing doses to achieve the same effect
• Withdrawal symptoms on dose reduction or cessation
• Craving: strong desire to take benzodiazepines
• Difficulty controlling use: unable to reduce despite desire
• Continued use despite harm: cognitive impairment, falls, social consequences

Withdrawal Syndrome (onset depends on half-life: hours for short-acting, days for long-acting)

• Psychological: anxiety (often severe, rebound), insomnia, irritability, poor concentration, depersonalisation, perceptual disturbances
• Physical: tremor, sweating, palpitations, headache, muscle pain and stiffness, nausea
• Severe withdrawal: seizures (generalised tonic-clonic), psychosis, delirium — potentially fatal
• Protracted withdrawal syndrome: symptoms may persist for weeks to months (sometimes years) — anxiety, insomnia, sensory disturbances, cognitive difficulties

Red Flags

• Seizures: risk highest with abrupt cessation of short-acting, high-dose benzodiazepines
• Psychosis: paranoid ideation, visual hallucinations — particularly with rapid withdrawal
• Suicidal ideation: depression and anxiety during withdrawal increase suicide risk
• Concurrent alcohol or opioid withdrawal: life-threatening — manage simultaneously with specialist input
• Elderly patients: increased sensitivity to benzodiazepines and withdrawal effects; higher falls risk
• Illicit benzodiazepine use: unknown substances and doses — greater unpredictability

Bedside

• Comprehensive drug history: all benzodiazepines and Z-drugs, doses, duration, source (prescribed vs illicit)
• Equivalent diazepam dose calculation: essential for planning reduction
• Urine drug screen: confirm benzodiazepine use, identify other substances
• Mental state examination: assess anxiety, depression, suicidality
• Falls risk assessment: especially in elderly patients

Bloods

• LFTs: concurrent alcohol-related liver disease
• FBC and U&Es: baseline
• TFTs: exclude thyrotoxicosis mimicking withdrawal
• Blood-borne virus screen: if illicit injecting drug use

Imaging

• Not routinely required
• CT/MRI head: if seizures with atypical features
• EEG: if diagnostic uncertainty about seizures

Special Tests

• Neuropsychological testing: if persistent cognitive concerns after withdrawal
• Sleep study: if persistent insomnia after withdrawal to exclude primary sleep disorder

Non-pharmacological

• Patient education: explain withdrawal process, expected timeline, reassurance that symptoms are self-limiting
• Psychological support: CBT for anxiety and insomnia (NICE CG113); sleep hygiene advice
• Gradual reduction plan: agreed collaboratively with patient; written schedule
• Regular review: GP or specialist follow-up every 2-4 weeks during reduction
• Self-help resources: benzodiazepine support groups, Ashton Manual (widely used patient resource)

Pharmacological

• Conversion to diazepam: convert total daily benzodiazepine/Z-drug dose to diazepam equivalent
• Approximate equivalences (to 5 mg diazepam):
  • Chlordiazepoxide 15 mg
  • Lorazepam 0.5 mg
  • Nitrazepam 5 mg
  • Temazepam 10 mg
  • Alprazolam 0.5 mg
  • Zopiclone 7.5 mg
• Reduction schedule: reduce by ~10-12.5% of current dose every 2-4 weeks; slow the rate of reduction as dose decreases
• Final stages: reductions of 0.5-1 mg diazepam at a time; may use liquid diazepam (2 mg/5 mL) for fine adjustments
• Total duration: typically 3-12 months depending on starting dose and individual response
• If seizures occur: stabilise on adequate benzodiazepine dose and restart slower reduction
• Adjunctive medications: propranolol for somatic anxiety symptoms; antidepressants if co-morbid depression

Surgical

• Not applicable

Referral Criteria

• Community drug and alcohol services: high-dose or illicit benzodiazepine dependence, polysubstance use
• Inpatient detoxification: severe dependence, history of withdrawal seizures, concurrent alcohol dependence, unstable social circumstances
• Psychiatry: co-morbid severe mental illness, suicidality, complex dual diagnosis
• Elderly care/falls clinic: older adults with benzodiazepine-related falls and cognitive impairment

Outcomes

• Successful dose reduction: approximately 60-80% of motivated patients can taper off benzodiazepines with gradual reduction and support
• Protracted withdrawal symptoms: may persist for 6-12 months in some patients; rarely years
• Seizure risk: primarily with abrupt cessation; very low risk with gradual reduction
• Cognitive recovery: most cognitive impairment improves within 6-12 months of cessation; some deficits may persist

Complications

• Seizures: potentially fatal; risk proportional to dose and rapidity of cessation
• Falls and fractures: particularly in elderly (benzodiazepines increase hip fracture risk by ~50%)
• Cognitive impairment: long-term use associated with increased risk of dementia (odds ratio ~1.5-2.0 in some studies)
• Road traffic accidents: increased risk while on benzodiazepines (impaired psychomotor function)
• Drug-related death: significant contributor to polydrug fatalities (synergy with opioids and alcohol)
• Rebound insomnia and anxiety: may be worse than pre-treatment levels initially

Benzodiazepine Equivalence Table

Ashton Manual Reduction Principles